Intra-Cellular Therapies Inc. (ITCI): Price and Financial Metrics
ITCI Price/Volume Stats
| Current price | $68.80 | 52-week high | $84.89 |
| Prev. close | $70.34 | 52-week low | $45.50 |
| Day low | $68.48 | Volume | 909,000 |
| Day high | $71.35 | Avg. volume | 933,643 |
| 50-day MA | $69.18 | Dividend yield | N/A |
| 200-day MA | $62.49 | Market Cap | 6.66B |
ITCI Stock Price Chart Interactive Chart >
Intra-Cellular Therapies Inc. (ITCI) Company Bio
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company was founded in 2002 and is based in New York, New York.
Latest ITCI News From Around the Web
Below are the latest news stories about INTRA-CELLULAR THERAPIES INC that investors may wish to consider to help them evaluate ITCI as an investment opportunity.
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out. |
3 Biotech Stocks Most Wall Street Analysts Are Bullish AboutHere we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals. |
Intra-Cellular Therapies Inc's EVP, Chief Medical Officer Suresh Durgam Sells 21,262 SharesIn a notable insider transaction, EVP and Chief Medical Officer Suresh Durgam of Intra-Cellular Therapies Inc (NASDAQ:ITCI) sold 21,262 shares of the company's stock on December 13, 2023. |
IBD 50 Stocks To Watch: Biotech Leader Intra-Cellular Therapies Is Breaking Out Past A New Buy PointBiotech leader Intra-Cellular Therapies is breaking out past a new buy point, making it one of the best stocks to buy and watch. |
ITCI Price Returns
| 1-mo | 0.53% |
| 3-mo | -0.29% |
| 6-mo | 22.33% |
| 1-year | 8.69% |
| 3-year | 105.80% |
| 5-year | 405.88% |
| YTD | -3.94% |
| 2023 | 35.34% |
| 2022 | 1.11% |
| 2021 | 64.59% |
| 2020 | -7.32% |
| 2019 | 201.23% |
Loading social stream, please wait...